Progesterone blocks multiple routes of ion flux

Molecular and Cellular Neuroscience

Volumn 48, Issue 2, 2011, Pages 137-141

  Kelley, Brooke G ^a   Mermelstein, Paul G ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Neuroprotection; Side effects; Steroid; Striatum; Traumatic brain injury

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DIHYDROPYRIDINE; NEUROTRANSMITTER RECEPTOR; PROGESTERONE; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; FEMALE; ION CURRENT; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STRIATE CORTEX;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; FEMALE; ION CHANNEL GATING; IONS; MALE; MEMBRANE POTENTIALS; NEURONS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 80052378777     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2011.07.002     Document Type: Article

References (47)

1. Ahmad A., Ahmad T., Sultan R.A., Murtaza G. Pharmacokinetic study of nifedipine in healthy adult male human volunteers. Trop. J. Pharm. Res. 2009, 8:385-391.
2. Allen G.S., Ahn H.S., Preziosi T.J., Battye R., Boone S.C., Boone S.C., Chou S.N., Kelly D.L., Weir B.K., Crabbe R.A., Lavik P.J., Rosenbloom S.B., Dorsey F.C., Ingram C.R., Mellits D.E., Bertsch L.A., Boisvert D.P., Hundley M.B., Johnson R.K., Strom J.A., Transou C.R. Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N. Engl. J. Med. 1983, 308:619-624.
3. Anderson L., Martin W., Higgins C., Nelson S.M., Norman J.E. The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy. Reprod. Sci. 2009, 16:1052-1061.
4. Atif F., Sayeed I., Ishrat T., Stein D.G. Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol. Med. 2009, 15:328-336.
5. Becker C., Jick S.S., Meier C.R. Use of antihypertensives and the risk of Parkinson disease. Neurol 2008, 70:1438-1444.
6. BHR Pharma LLC efficacy and safety study of intravenous progesterone in patients with severe traumatic brain injury (SyNAPSe) Available from:, NLM Identifier: NCT0114306. http://clinicaltrials.gov/ct2/show/NCT01143064.
7. Bielefeldt K., Abboud M., Conklin J.L. Nongenomic effects of progesterone intestinal smooth muscle cells. Am. J. Physiol. 1996, 271:370-376.
8. Borna S., Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust. N. Z. J. Obstet. Gynaecol. 2008, 48:58-63.
9. Chien S.C., Uang Y.S., Lin H.Y., Hsu K.Y. Pharmacokinetics of nifedipine in Taiwanese. Biopharm. Drug Dispos. 2004, 25:77-84.
10. Das P., Bell-Horner C.L., Huang R.Q., Raut A., Gonzales E.B., Chen Z.L., Covey D.F., Dillon G.H. Inhibition of type A GABA receptors by L-type calcium channel blockers. Neurosci 2004, 124:195-206.
11. Ehring G.R., Kerschbaum H.H., Eder C., Neben A.L., Fanger C.M., Khoury R.M., Negulescu P.A., Cahalan M.D. A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes. J. Exp. Med. 1998, 188:1593-1602.
12. Gellersen B., Fernandes M.S., Brosens J.J. Non-genomic progesterone actions in female reproduction. Hum. Reprod. Update 2009, 15:119-138.
13. Gelmers H.J. Calcium-channel blockers in the treatment of migraine. Am. J. Cardiol. 1985, 55:139-143.
14. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharm 2008, 55:363-389.
15. Goodnick P.J. The use of nimodipine in the treatment of mood disorders. Bipolar Disord. 2000, 2:165-173.
16. Goss C.W., Hoffman S.W., Stein D.G. Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol. Biochem. Behav. 2003, 76:231-242.
17. Hoffman, S.W., Kellermann, A.L., Stein, D.G., Wright, D.W., Lowery-North, D.W. (2008) Methods for the treatment of a traumatic central nervous injury, US Patent 7915244.
18. Hurd C., Moudgil V.K. Characterization of R5020 and RU486 binding to progesterone receptor from calf uterus. Biochem 1988, 27:3618-3623.
19. Ilijic E., Guzman J.N., Surmeier D.J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 2011, 43:364-371.
20. Judge S.I., Lee J.M., Bever C.T., Hoffman P.M. Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J. Rehabil. Res. Dev. 2006, 43:111-122.
21. Khan A., Langley S.J., Mullins F.G., Dixon J.S., Toon S. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br. J. Clin. Pharmacol. 1991, 32:519-522.
22. King J.F., Flenady V.J., Papatsonis D.N., Dekker G.A., Carbonne B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst. Rev. 2003, 1:CD002255.
23. Kittaka M., Giannotta S.L., Zelman V., Correale J.D., DeGiorgio C.M., Weiss M.H., Zlokovic B.V. Attenuation of brain injury and reduction of neuron-specific enolase by nicardipine in systemic circulation following focal ischemia and reperfusion in a rat model. J. Neurosurg. 1997, 87:731-737.
24. Lancel M., Faulhaber J., Holsboer F., Rupprecht R. Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am. J. Physiol. 1996, 271:763-772.
25. Luoma J.I., Kelley B.G., Mermelstein P.G. Progesterone inhibition of voltage-gated calcium channels is a potential neuroprotective mechanism against excitotoxicity. Steroids 2011, 76:845-855.
26. Lyell D.J., Pullen K.M., Mannan J., Chitkara U., Druzin M.L., Caughey A.B., El-Sayed Y.Y. Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial. Obstet. Gynecol. 2008, 112:1221-1226.
27. Mermelstein P.G., Bito H., Deisseroth K., Tsien R.W. Critical dependence of cAMP response element-binding protein phosphorylation on L-type calcium channels supports a selective response to EPSPs in preference to action potentials. J. Neurosci. 2000, 20:266-273.
28. Myers M.G. Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects. J. Hypertens. Suppl. 1994, 12:S73-S76.
29. Pedrinelli R., Dell'Omo G., Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J. Hum. Hypertens. 2001, 15:455-461.
30. Putnam C.D., Brann D.W., Kolbeck R.C., Mahesh V.B. Inhibition of uterine contractility by progesterone and progesterone metabolites: mediation by progesterone and gamma amino butyric acidA receptor systems. Biol. Reprod. 1991, 45:266-272.
31. Renwick A.G., Robertson D.R., Macklin B., Challenor V., Waller D.G., George C.F. The pharmacokinetics of oral nifedipine-a population study. Br. J. Clin. Pharmacol. 1988, 25:701-708.
32. Ritz B., Rhodes S.L., Qian L., Schernhammer E., Olsen J.H., Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 2010, 67:600-606.
33. Robertson D.R., Waller D.G., Renwick A.G., George C.F. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br. J. Clin. Pharmacol. 1988, 25:297-305.
34. Robertson C.L., Puskar A., Hoffman G.E., Murphy A.Z., Saraswati M., Fiskum G. Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp. Neurol. 2006, 197:235-243.
35. Rosendorff C. Hypertension and coronary artery disease: a summary of the American Heart Association scientific treatment. J. Clin. Hypertens. 2007, 9:790-795.
36. Sayeed I., Guo Q., Hoffman S.W., Stein D.G. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann. Emerg. Med. 2006, 47:381-389.
37. Selye H. Correlations between the chemical structure and the pharmacological actions of the steroids. Endo 1942, 30:437-453.
38. Shear D.A., Galani R., Hoffman S.W., Stein D.G. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp. Neurol. 2002, 178:59-67.
39. Wang Y., Yang P.L., Tang J.F., Lin J.F., Cai X.H., Wang X.T., Zheng G.Q. Potassium channels: possible new therapeutic targets in Parkinson's disease. Med. Hypotheses 2008, 71:546-550.
40. Wright D.W., Bauer M.E., Hoffman S.W., Stein D.G. Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J. Neurotrauma 2001, 18:901-909.
41. Wright D.W., Ritchie J.C., Mullins R.E., Kellermann A.L., Denson D.D. Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J. Clin. Pharmacol. 2005, 45:460-468.
42. Wright D.W., Kellermann A.L., Hertzberg V.S., Clark P.L., Frankel M., Goldstein F.C., Salomone J.P., Dent L.L., Harris O.A., Ander D.S., Lowery D.W., Patel M.M., Denson D.D., Gordon A.B., Wald M.M., Gupta S., Hoffman S.W., Stein D.G. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 2007, 49:391-402.
43. Xiao G., Wei J., Yan W., Wang W., Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 2008, 12:R61.
44. Yatani A., Brown A.M. The calcium channel blocker nitrendipine blocks sodium channels in neonatal rat cardiac myocytes. Circ. Res. 1985, 56:868-875.
45. Zhang X., Gold M.S. Dihydropyridine block of voltage-dependent K+ currents in rat dorsal root ganglion neurons. Neurosci 2009, 161:184-194.
46. Zhang X., Anderson J.W., Fedida D. Characterization of nifedipine block of the human heart delayed rectifier, hKv1.5. J. Pharmacol. Exp. Ther. 1997, 281:1247-1256.
47. Zhang M., Benishin C.G., Pang P.K.T. Rapid inhibition of the contraction of rat tail artery by progesterone is mediated by inhibition of calcium currents. J. Pharm. Pharm. 2002, 54:1667-1674.